AUS
NZ
UK
CA
USA
IND
Highlights
- Leqembi's subcutaneous autoinjector (SC-AI) could become the only FDA-approved at-home injectable Alzheimer's treatment.
- The quick 15-second injection process simplifies administration and could reduce hospital visits.
- Leqembi is already approved in major markets including the US, Japan, China, and Great Britain.
BioArctic AB (NASDAQ:BIOA) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) submitted by their partner Eisai for Leqembi's subcutaneous autoinjector (SC-AI) for weekly maintenance dosing. The FDA's Prescription Drug User Fee Act (PDUFA) action date for this application is set for August 31, 2025. This marks a critical step forward for Leqembi, an innovative treatment for early Alzheimer's disease, potentially revolutionizing the way patients receive care.
Leqembi, which has already been approved in several major global markets, is currently available for patients in the U.S., Japan, China, Great Britain, and has received a positive opinion from the European Medicines Agency (EMA) for approval in the European Union in November 2024. This new subcutaneous delivery method would offer patients the convenience of at-home administration, reducing the need for frequent hospital visits and injections, a significant shift for Alzheimer's treatment.
The SC-AI formulation provides a 360 mg weekly maintenance regimen after an initial biweekly intravenous (IV) initiation phase. The new at-home treatment option is designed for easy administration in just a 15-second injection process, allowing patients or their caregivers to administer the drug with ease. This convenience, combined with the reduction in healthcare facility visits, could significantly simplify the treatment journey for Alzheimer's patients, ensuring they maintain both clinical and biomarker benefits while offering a more comfortable and cost-effective alternative to traditional intravenous treatments.
Leqembi is already a significant player in the Alzheimer's treatment landscape, and the addition of this convenient SC-AI delivery method could make it the only FDA-approved anti-amyloid therapy with the potential for at-home administration. The ability to self-administer treatment weekly could enhance patient adherence to therapy and ease the burden on healthcare systems. Furthermore, this approach could also reduce the financial burden associated with hospital visits, making it an attractive option for patients and healthcare providers alike.
While the FDA approval of the subcutaneous form is still pending, BioArctic's partnership with Eisai and the potential approval of the SC-AI version of Leqembi represents a major milestone in the ongoing fight against Alzheimer's disease. The innovative delivery method, combined with the treatment's established efficacy, has the potential to significantly improve the quality of life for patients and their families.
The FDA's decision, scheduled for August 2025, will be a critical moment for the Alzheimer's disease treatment landscape, and BioArctic’s collaboration with Eisai will likely continue to play an essential role in shaping the future of the disease's management. As Leqembi expands its reach across new markets, its subcutaneous autoinjector could be a game-changer for both patient care and the broader healthcare system.
